biostudies-literatureUnknown18(2)Wiseman CL<h4>Background</h4>SV-BR-1-GM, derived from a patient with grade 2 (moderately differentiated) breast cancer, is a GM-CSF-secreting breast cancer cell line with properties of antigen-presenting cells. SV-BR-1-GM and next-generation versions are covered by several pending and granted patents.<h4>Methods</h4>We report findings from an open-label phase I, single-arm pilot study with irradiated SV-BR-1-GM cells in 3 breast and 1 ovarian cancer subjects. Inoculations were preceded by lowdose intravenous cyclophosphamide and followed by interferon-alpha2b injections into the SVBR- 1-GM inoculation sites. We assessed both cellular and humoral immune responses, and measured expression levels of SV-BR-1-GM HLA alleles.<h4>Results</h4>Treatment was generally safe and well tolerated. Immune responsesRecent patents on anti-cancer drug discovery224-240https://www.ebi.ac.uk/biostudies/studies/S-EPMC10009895biostudies-literatureRegression of Breast Cancer Metastases Following Treatment with Irradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer Cell Line: Intellectual Property and Immune Markers of Response.PMC10009895Williams WVDozio VMacuchova ESunkari VGLacher MDKharazi AHashwah HWiseman CLGaleas JLfalseRegression of Breast Cancer Metastases Following Treatment with Irradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer Cell Line: Intellectual Property and Immune Markers of Response.<h4>Background</h4>SV-BR-1-GM, derived from a patient with grade 2 (moderately differentiated) breast cancer, is a GM-CSF-secreting breast cancer cell line with properties of antigen-presenting cells. SV-BR-1-GM and next-generation versions are covered by several pending and granted patents.<h4>Methods</h4>We report findings from an open-label phase I, single-arm pilot study with irradiated SV-BR-1-GM cells in 3 breast and 1 ovarian cancer subjects. Inoculations were preceded by lowdose intravenous cyclophosphamide and followed by interferon-alpha2b injections into the SVBR- 1-GM inoculation sites. We assessed both cellular and humoral immune responses, and measured expression levels of SV-BR-1-GM HLA alleles.<h4>Results</h4>Treatment was generally safe and well tolerated. Immune responses2022-01-01T00:00:00Z20222026-05-14T03:19:25.617Z2025-04-06T16:28:03.927ZS-EPMC100098953559334010.2174/1574892817666220518123331